WVP
HEPA

Worth Venture Partners’s Hepion Pharmaceuticals HEPA Stock Holding History

Worth Venture Partners’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-234
Closed -$512K – 120
2020
Q4 		$512K Buy
+234
New +$606K 0.41% 61

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Worth Venture Partners's HEPA Position: Q1 2021 in Review

Worth Venture Partners sold out of Hepion Pharmaceuticals (HEPA) in Q1 2021, closing a stake of 234 shares — an estimated $512K sold.

Worth Venture Partners first reported a position in HEPA in Q4 2020 and held it in 1 quarter. The position peaked at $512K in Q4 2020. 38 funds tracked by Wall St. Rank hold HEPA as of Q1 2021.

  • Worth Venture Partners reported no remaining Hepion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 234 Hepion Pharmaceuticals shares in Q1 2021, an estimated $512K.
  • Worth Venture Partners first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Worth Venture Partners's Hepion Pharmaceuticals position peaked at $512K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.